JPMorgan Chase & Co. Has $1.32 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

JPMorgan Chase & Co. reduced its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 70.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,954 shares of the company's stock after selling 676,735 shares during the period. JPMorgan Chase & Co. owned about 0.57% of Cabaletta Bio worth $1,321,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in CABA. Point72 Asia Singapore Pte. Ltd. bought a new position in Cabaletta Bio during the third quarter worth $32,000. Point72 DIFC Ltd acquired a new stake in shares of Cabaletta Bio during the third quarter worth $33,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Cabaletta Bio by 65.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company's stock worth $44,000 after buying an additional 3,724 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Cabaletta Bio in the 3rd quarter valued at about $67,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Cabaletta Bio during the 3rd quarter valued at about $127,000.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Evercore ISI downgraded Cabaletta Bio from an "outperform" rating to an "inline" rating and decreased their target price for the company from $15.00 to $6.00 in a research note on Friday, December 20th. TD Cowen upgraded Cabaletta Bio to a "strong-buy" rating in a research report on Friday, November 29th. Wells Fargo & Company lowered Cabaletta Bio from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $12.00 to $6.00 in a research report on Thursday, December 19th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price target on shares of Cabaletta Bio in a report on Friday, January 17th. Finally, William Blair restated an "outperform" rating on shares of Cabaletta Bio in a research note on Monday, November 18th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.38.

Cabaletta Bio Stock Performance

NASDAQ:CABA traded down $0.09 during trading hours on Friday, hitting $2.50. 1,006,504 shares of the company's stock traded hands, compared to its average volume of 1,286,971. The stock's fifty day moving average price is $2.62 and its two-hundred day moving average price is $4.25. The firm has a market cap of $122.20 million, a P/E ratio of -1.16 and a beta of 2.46. Cabaletta Bio, Inc. has a twelve month low of $1.76 and a twelve month high of $26.35.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.